Meet the Expert
Dr Blauvelt on the most exciting news from this year’s AAD
Interview with
Dr Andrew Blauvelt, University of Maryland School of Medicine, MD, USA
At this year’s American Academy of Dermatology Annual Meeting 2026, Dr Blauvelt highlighted a clear shift towards highly effective oral therapies in psoriasis, particularly next-generation tyrosine kinase 2 (TYK2) inhibitors demonstrating biologic-like efficacy. In atopic dermatitis (AD), he emphasised the growing and increasingly diverse pipeline, including agents such as amlitelimab with potential disease-modifying effects and long-acting interleukin-13 (IL-13) inhibitors. He also pointed to the expansion of treatment options in high-unmet-need areas, such as hidradenitis suppurativa (HS) and vitiligo, where oral Janus kinase (JAK) inhibitors are expected to play an important role.